Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT

被引：0

作者：

H-Y Yhim

K Kim

J S Kim

H J Kang

J-A Kim

C-K Min

S H Bae

E Park

D-H Yang

C Suh

M K Kim

Y-C Mun

H S Eom

H J Shin

H-J Yoon

J H Kwon

J H Lee

Y S Kim

S-S Yoon

J-Y Kwak

机构：

[1] Chonbuk National University Medical School,Department of Internal Medicine

[2] Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital,Department of Medicine, Division of Hematology and Oncology

[3] Samsung Medical Center,Department of Internal Medicine, Division of Hematology

[4] Sungkyunkwan University School of Medicine,Department of Internal Medicine

[5] Yonsei University College of Medicine,Department of Hematology

[6] Korea Cancer Center Hospital,Department of Hematology

[7] St Vincent Hospital,Department of Internal Medicine

[8] Catholic University of Korea College of Medicine,Department of Hematology–Oncology

[9] Kangnam St Mary’s Hospital,Department of Oncology

[10] Catholic University of Korea College of Medicine,Department of Internal Medicine

[11] Daegu Catholic University Medical Center,Department of Internal Medicine

[12] Department of Internal Medicine Chung-Ang University College of Medicine,Department of Internal Medicine

[13] Chonnam National University Hwasun Hospital,Department of Hematology–Oncology

[14] Asan Medical Center,Department of Internal Medicine

[15] University of Ulsan College of Medicine,Department of Internal Medicine

[16] Yeungnam University College of Medicine,Department of Internal Medicine

[17] Ewha Woman’s University School of Medicine,Department of Internal Medicine

[18] Center for Specific Organs Cancer,undefined

[19] National Cancer Center of Korea,undefined

[20] Pusan National University School of Medicine,undefined

[21] School of Medicine,undefined

[22] Kyung Hee University,undefined

[23] Kangdong Sacred Heart Hospital,undefined

[24] Hallym University Medical Center,undefined

[25] Gachon University Gil Hospital,undefined

[26] Kosin University Gospel Hospital,undefined

[27] Seoul National University College of Medicine,undefined

来源：

Bone Marrow Transplantation | 2013年 / 48卷

关键词：

auto-SCT; multiple myeloma; salvage therapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The aims of this study were to investigate the outcomes of second salvage auto-SCT and to identify the impacts of a second auto-SCT compared with systemic chemotherapy alone on disease outcome. Data from 48 patients who underwent second auto-SCT were matched to 144 patients (1:3) who received systemic chemotherapy alone from the Korean Myeloma Registry. Groups were matched for nine potential prognostic factors and compared for treatment outcomes. The median age of matching-pairs at relapse was 55.5 years. A total of 156 patients (81%) received vincristine, doxorubicin and dexamethasone induction therapy before the first auto-SCT. Thirty-five patients (73%) in the second auto-SCT group received novel agent-based therapies before the second auto-SCT, and similar proportion in both groups received novel therapies after relapse of front-line auto-SCT. With a median follow-up of 55.3 months, patients who underwent a second auto-SCT had significantly better median OS (55.5 vs 25.4 months, P=0.035). In multivariate analysis for OS, <18 months time to progression after first auto-SCT, International Staging System III and salvage chemotherapy alone were independent predictors for worse OS. The outcomes of second auto-SCT appear to be superior to those of systemic chemotherapy alone. A randomized trial comparing both treatment strategies is required.

引用

页码：425 / 432

页数：7

共 148 条

[1]

Attal M(1996)A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 335 91-97

[2]

Harousseau JL(2003)High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 1875-1883

[3]

Stoppa AM(2007)Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2123-2132

[4]

Sotto JJ(2007)Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 2133-2142

[5]

Fuzibet JG(2005)Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2487-2498

[6]

Rossi JF(2007)Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 3557-3560

[7]

Child JA(2011)Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival Biol Blood Marrow Transplant 18 773-779

[8]

Morgan GJ(2009)Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma Bone Marrow Transplant 43 417-422

[9]

Davies FE(2006)Prolonged overall survival with second on-demand autologous transplant in multiple myeloma Am J Hematol 81 426-431

[10]

Owen RG(2011)Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation Leuk Lymphoma 52 1455-1462

← 1 2 3 4 5 6 7 8 9 10 →